PharmaVentures is pleased to announce it recently acted as exclusive M&A advisor to capiton AG on the sale of MiP’s sterile production site in Homburg /Saar, Germany to FAMAR, a globally operating pharmaceutical and cosmetic CDMO.

Under capiton’s ownership, the MiP manufacturing facility has been transformed into a state-of-the-art world class manufacturing facility. FAMAR intend to build on this further to strengthen its supply chain to meet the growing demand for its pharmaceutical services.

The pharmaceutical services sector that includes CROs, CDMOs and other specialist consultancies continues to evolve and transactions such as this are a key driver for the growth of Pharmaceutical Services companies.

“We are pleased to have assisted capiton AG in the divestment of MiP’s manufacturing site in Homburg to MidEuropa-backed FAMAR. This transaction forms a successful part of MiPs strategic plan and gives FAMAR access to a world-class manufacturing facility with space for growth.” said Soren Demin, Head of M&A at PharmaVentures.

“This transaction illustrates the important role of specialist advisors such as PharmaVentures play in the execution of these transformative deals,” said Dr Fintan Walton, CEO and Founder of PharmaVentures. “Our decades of experience in M&A, together with our detailed knowledge of the pharmaceutical services industry enabled us to deliver the optimal deal for our client.”